Skip to main
  1. Stocks
  2. OptimizeRx Corp
  3. Forecast
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx is increasingly attractive because its revenue reset appears to reflect known customer and managed-service headwinds rather than weakening demand, while the underlying platform is producing stronger profitability and cash flow. In 3Q, revenue was $21.6M, EBITDA reached $6.3M with a 29.1% margin, gross margin expanded to 75.2%, and free cash flow was $4.7M, showing meaningful operating leverage as the cost base resets lower. The balance sheet has also improved to net cash, contracted revenue for 2027 is running about 20% ahead of last year, and new programmatic DSP integrations plus the return of a top-5 client create credible upside.

Bears say

OptimizeRx is facing a fundamentally fragile revenue base, with net revenue retention dropping to 90% from 121% and three customers each accounting for more than 10% of 2025 revenue, while roughly 62% of 2025 revenue flowed through just two channel partners. This concentration leaves the business exposed to partner leverage, customer budget shifts, and execution missteps, especially after management acknowledged that commercial execution issues contributed to the loss of a major customer relationship. At the same time, the May 2025 executive order, the December 2025 CMS MFN proposal, and IRA drug-pricing pressure threaten the pharma marketing budgets that support demand, while the unwind of lower-margin managed services could create near-term revenue volatility if automation does not scale fast enough.

OptimizeRx Corp (OPRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction

Get the latest OptimizeRx Corp (OPRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OptimizeRx Corp (OPRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 6 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction

Get the latest OptimizeRx Corp (OPRX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in OptimizeRx Corp (OPRX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover OPRX stock data and trends